Increased Serum Osteoprotegerin Level in Older and Diabetic Hemodialysis Patients
- 1 August 2004
- journal article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 8 (4) , 335-339
- https://doi.org/10.1111/j.1526-0968.2004.00159.x
Abstract
Osteoprotegerin is a circulating osteoclastogenesis inhibitory factor and serum osteoprotegerin levels are elevated in hemodialysis patients. This study investigated whether osteoprotegerin levels correlated with various clinical parameters in hemodialysis patients. The subjects were 45 men and 37 women aged from 27 to 94 years (mean = 60.4 +/- 13.9 years), and the duration of dialysis was 9-277 months (mean = 89.5 +/- 64.7 months). Serum osteoprotegerin levels were measured by enzyme-linked immunosorbent assay. Data were analyzed by stepwise multiple regression analysis. The mean osteoprotegerin level of the hemodialysis patients was 303 +/- 210 pg/mL, which was higher than in age-matched healthy controls. Osteoprotegerin levels increased with age, a longer duration of dialysis, and the presence of diabetes. Skeletal resistance to parathyroid hormone might be increased by aging, a long dialysis period, and diabetes, perhaps explaining why adynamic bone disease is more common in older or diabetic patients.Keywords
This publication has 16 references indexed in Scilit:
- Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failureAmerican Journal of Kidney Diseases, 2002
- Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biologyJournal of Molecular Medicine, 2001
- In Vivo Demonstration that Human Parathyroid Hormone 1–38 Inhibits the Expression of Osteoprotegerin in Bone with the Kinetics of an Immediate Early GeneJournal of Bone and Mineral Research, 2000
- Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with Osteoclast-Like Cell Formation*Endocrinology, 1999
- Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand FamiliesEndocrine Reviews, 1999
- Serum Interleukin-6 in Renal Osteodystrophy: Relationship with Serum PTH and Bone Remodeling MarkersHormone and Metabolic Research, 1999
- Osteotropic Agents Regulate the Expression of Osteoclast Differentiation Factor and Osteoprotegerin in Osteoblastic Stromal CellsEndocrinology, 1998
- Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapyKidney International, 1994
- Elevated circulating levels of interleukin-6 in patients with chronic renal failureKidney International, 1991
- Skeletal Resistance to Parathyroid Hormone in Renal FailureAnnals of Internal Medicine, 1973